Boswellia resin: From religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 10, 2009, Pages 1281-1293

  Moussaieff, Arieh ^a   Mechoulam, Raphael ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Boswellia; Boswellic acids; Frankincense; Incensole; Olibanum

Indexed keywords

ACETIC ACID; BETA BOSWELLIC ACID; BOSWELLIA SERRATA EXTRACT; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; RESIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRITERPENOID; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BOSWELLIC ACID; CYTOTOXIN; DITERPENE; INCENSOLE ACETATE; PLANT RESIN; TRITERPENE;

ARTHRITIS; ATHEROSCLEROSIS; BOSWELLIA; CALCIUM MOBILIZATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CULTURAL FACTOR; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENTERITIS; HISTORY OF MEDICINE; HUMAN; IC 50; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; MEDICINAL PLANT; NEOPLASM; NEUROPROTECTION; NONHUMAN; RELIGION; REVIEW; TRAUMATIC BRAIN INJURY; WOUND HEALING; ANIMAL; APOPTOSIS; BRAIN; CHEMISTRY; DRUG EFFECT; DRUG SCREENING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BOSWELLIA; BRAIN; CLINICAL TRIALS AS TOPIC; CYTOTOXINS; DITERPENES; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOMODULATION; NF-KAPPA B; RESINS, PLANT; TRITERPENES;

EID: 74949117177     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.10.0003     Document Type: Review

References (113)

1. Vollesen K. In: Hedberg I, Eduards S. (eds) Flora of Ethiopia. Ethiopia: Addis Ababa and Asmara, 1989: 442-446.
2. Michie CA, Cooper E. Frankincense and myrrh as remedies in children. J R Soc Med 1991; 84: 602-605.
3. Marshall S. Frankincense: festive pharmacognosy. Pharm J 2003; 271: 862-864.
4. Gunther RT. The Greek Herbal of Dioscorides. New York: Hafner, 1959.
5. Shachter J, Epstein I. (eds). The Babylonian Talmud. New York: Seder Nezikin, Sanhedrin tractate, The Suncino Press, 1935.
6. Koskenniemi E et al. Wine mixed with myrrh (Mark 15.23) and Crurifragium (John 19.31-32): two details of the Passion Narratives. J Study New Testament 2005; 27: 379-391.
7. Abdul Hameed H. ed. Avicenna's Tract on Cardiac Drugs and Essays on Arab Cardiotherapy. New Delhi: Hamdard Foundation Press, 1983.
8. Encyclopaedia Britannica, 15th edn. Chicago: Micropaedia, University of Chicago, 1975.
9. Uphof JC. Dictionary of Economic Plants. 2nd edn. Stuttgart: Medpharm GmbH Scientific Publishers, 1968.
10. Getahon A. Some Common Medicinal and Poisonous Plants Used in Ethiopian Folkmedicine, Mimeographed. Addis Ababa: Addis Ababa University, 1976.
11. Frawley D, Lad V. The Yoga of Herbs: an Ayurvedic Guide to Herbal Medicine. Delhi: Motilal Banarsidass Publications, 1997.
12. Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med 2006; 12: 1100-1116.
13. Hamm S et al. A chemical investigation by headspace SPME and GC-MS of volatile and semi-volatile terpenes in various olibanum samples. Phytochemistry 2005; 66: 1499-1514.
14. Safayhi H et al. Concentration-dependent potentiating and inhibitory effects of Boswellia extracts on 5-lipoxygenase product formation in stimulated PMNL. Planta Med 2000; 66: 110-113.
15. Poeckel D, Werz O et al. Boswellic acids: biological actions and molecular targets. Curr Med Chem 2006; 13: 3359-3369.
16. Winterstein A, Stein G. Untersuchungen in der Saponinreihe Zur Kenntnis der Mono-oxy-triterpensäuren. Hoppe-Seyler's Z Physiol Chem 1932; 208: 9-25.
17. Büchele B et al. Characterization of 3alpha-acetyl-11-keto- alpha-boswellic acid, a pentacyclic triterpenoid inducing apoptosis in vitro and in vivo. Planta Med 2006; 72: 1285-1289.
18. Boden SE et al. Stimulation of leukotriene synthesis in intact polymorphonuclear cells by the 5-lipoxygenase inhibitor 3-oxo-tirucallic acid. Mol Pharmacol 2001; 60: 267-273.
19. Moussaieff A et al. Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol Pharmacol 2007; 72: 1657-1664.
20. Corsano S, Nicoletti R. The structure of incensole. Tetrahedron 1967; 23: 1977-1984.
21. Moussaieff A et al. Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab 2008; 28: 1341-1352.
22. Moussaieff A et al. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J 2008; 22: 3024-3034.
23. Roy S et al. Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells. DNA Cell Biol 2005; 24: 244-255.
24. Karin M. Inflammation-activated protein kinases as targets for drug development. Proc Am Thorac Soc 2005; 2: 386-390.
25. Perkins ND et al. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
26. Pikarsky E, Ben-Neriah Y. NF-kappaB inhibition: a double-edged sword in cancer? Eur J Cancer 2006; 42: 779-784.
27. Syrovets T et al. Acetyl-boswellic acids inhibit lipopolysac-charide-mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinases. J Immunol 2005; 174: 498-506.
28. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008; 9: 162-176.
29. Evans JF et al. What's all the FLAP about?: 5-lipoxygenase- activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008; 29: 72-78.
30. Garcia C et al. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res 1996; 11: 1619-1627.
31. Sveinbjörnsson B et al. Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. FASEB J 2008; 22: 3525-3536.
32. Avis I et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have super-additive effects on lung cancer growth inhibition. Cancer Res 2005; 65: 4181-4190.
33. Montuschi P. Leukotrienes, antileukotrienes and asthma. Mini Rev Med Chem 2008; 8: 647-656.
34. Bäck M et al. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 2005; 102: 17501-17506.
35. Bevan S et al. Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations. Stroke 2008; 39: 1109-1114.
36. Ammon HP et al. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata. Planta Med 1991; 57: 203-207.
37. Safayhi H et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992; 261: 1143-1146.
38. Safayhi H et al. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol 1995; 47: 1212-1216.
39. Sailer ER et al. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 1996; 117: 615-618.
40. Werz O et al. Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 1998; 54: 445-451.
41. Sailer ER et al. Characterization of an acetyl-11-keto-beta- boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem 1998; 256: 364-368.
42. Poeckel D et al. Boswellic acids stimulate arachidonic acid release and 12-lipoxygenase activity in human platelets independent of Ca2+ and differentially interact with platelet-type 12-lipoxygenase. Mol Pharmacol 2006; 70: 1071-1078.
43. Altmann A et al. Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes. Br J Pharmacol 2004; 141: 223-232.
44. Siemoneit U et al. Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Biochem Pharmacol 2008; 75: 503-513.
45. Poeckel D et al. 3-O-acetyl-11-keto-boswellic acid decreases basal intracellular Ca2+ levels and inhibits agonist-induced Ca2+ mobilization and mitogen-activated protein kinase activation in human monocytic cells. J Pharmacol Exp Ther 2006; 316: 224-232.
46. Jeffrey KL et al. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 2007; 6: 391-403.
47. Altmann A et al. Boswellic acids activate p42(MAPK) and p38 MAPK and stimulate Ca(2+) mobilization. Biochem Biophys Res Commun 2002; 290: 185-190.
48. Poeckel D et al. Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid. Br J Pharmacol 2005; 146: 514-524.
49. Safayhi H et al. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther 1997; 281: 460-463.
50. Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 2006; 1112: 255-262.
51. Weber CC et al. Modulation of Pgp function by boswellic acids. Planta Med 2006; 72: 507-513.
52. Glaser T et al. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer 1999; 80: 756-765.
53. Hoernlein RF et al. Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J Pharmacol Exp Ther 1999; 288: 613-619.
54. Hostanska K et al. Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro. Anticancer Res 2002; 22: 2853-2862.
55. Xia L et al. Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells. Mol Cancer Ther 2005; 4: 381-388.
56. Liu JJ et al. Keto- and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. Int J Mol Med 2002; 10: 501-505.
57. Liu JJ et al. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 2002; 23: 2087-2093.
58. Liu JJ et al. Acetyl-keto-beta-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells. Br J Pharmacol 2006; 148: 1099-1107.
59. Yuan HQ et al. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol 2008; 75: 2112-2121.
60. Lu M et al. Acetyl-keto-beta-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer Res 2008; 68: 1180-1186.
61. Zhao W et al. Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detect Prev 2003; 27: 67-75.
62. Syrovets T et al. Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 2005; 280: 6170-6180.
63. Shao Y et al. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med 1998; 64: 328-331.
64. Huang MT et al. Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid. Biofactors 2000; 13: 225-230.
65. Jing Y et al. Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. Leuk Res 1999; 23: 43-50.
66. Syrovets T et al. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. Mol Pharmacol 2000; 58: 71-81.
67. Kiela PR et al. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am J Physiol Gastrointest Liver Physiol 2005; 288: G798-G808.
68. Takada Y et al. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J Immunol 2006; 176: 3127-3140.
69. Shah B et al. Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids. Bioorg Med Chem Lett 2007; 17: 6411-6416.
70. Singh SK et al. Effect of acetyl 11-keto beta-boswellic acid on metastatic growth factor responsible for angiogenesis. Vascul Pharmacol 2007; 46: 333-337.
71. Bhushan S et al. A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells. Apoptosis 2007; 12: 1911-1926.
72. Christensen AP, Corey DP. TRP channels in mechanosensation: direct or indirect activation? Nat Rev Neurosci 2007; 8: 510-521.
73. Smith GD et al. TRPV3 is a temperature-sensitive vanilloid receptor-like protein. Nature 2002; 418: 186-190.
74. Dhaka A et al. TRP ion channels and temperature sensation. Annu Rev Neurosci 2006; 29: 135-161.
75. Minke B. TRP channels and Ca2+ signaling. Cell Calcium 2006; 40: 261-275.
76. Khanna D et al. Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 2007; 7: 344-351.
77. Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 1986; 18: 407-412.
78. Singh S et al. Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats. Bioorg Med Chem Lett 2007; 17: 3706-3711.
79. Khajuria A et al. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg. Vaccine 2007; 25: 4586-4594.
80. Khajuria A et al. Immunomodulatory activity of biopolymeric fraction BOS 2000 from Boswellia serrata. Phytother Res 2008; 22: 340-348.
81. Sharma ML et al. Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis. Int J Immunopharmacol 1989; 11: 647-652.
82. Reddy GK et al. Urinary excretion of connective tissue metabolites under the influence of a new non-steroidal anti-inflammatory agent in adjuvant induced arthritis. Agents Actions 1987; 22: 99-105.
83. Reddy GK et al. Studies on the metabolism of glycosaminoglycans under the influence of new herbal anti-inflammatory agents. Biochem Pharmacol 1989; 38: 3527-3534.
84. Fan AY et al. Effects of an acetone extract of Boswellia carterii Birdw. (Burseraceae) gum resin on adjuvant-induced arthritis in lewis rats. J Ethnopharmacol 2005; 101: 104-109.
85. Krieglstein CF et al. Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 2001; 16: 88-95.
86. Anthoni C et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1131-G1137.
87. Borrelli F et al. Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhoea without constipation. Br J Pharmacol 2006; 148: 553-560.
88. Cuaz-Pérolin C et al. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. Arterioscler Thromb Vasc Biol 2008; 28: 272-277.
89. Winking M et al. Boswellic acids inhibit glioma growth: a new treatment option? Neurooncology 2000; 46: 97-103.
90. Moussaieff A et al. The Jerusalem Balsam: from the Franciscan monastery in the old city of Jerusalem to Martindale 33. J Ethnopharmacol 2005; 101: 16-26.
91. Camarda L et al. Chemical composition and antimicrobial activity of some oleogum resin essential oils from Boswellia spp. (Burseraceae). Ann Chim 2007; 97: 837-844.
92. Schillaci D et al. In vitro anti-biofilm activity of Boswellia spp. oleogum resin essential oils. Lett Appl Microbiol 2008; 47: 433-438.
93. Schuhmann MU et al. Effect of Boswellia carterii on brain edema following contusion injury. J Cereb Blood Flow Metab 2005; 25: 261.
94. Kar A, Menon MK. Analgesic effect of the gum resin of Boswellia serata Roxb. Life Sci 1969; 8: 1023-1028.
95. Menon MK, Kar A. Analgesic and psychopharmacological effects of the gum resin of Boswellia serrata. Planta Med 1971; 19: 333-341.
96. Ernst E et al. Frankincense: systematic review. Br Med J 2008; 337: a2813.
97. Gupta I et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 1998; 3: 511-514.
98. Gupta I et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001; 67: 391-395.
99. Sengupta K et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther 2008; 10: R85.
100. Streffer JR et al. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. Neurology 2001; 56: 1219-1221.
101. Fan AY et al. Effects of an acetone extract of Boswellia carterii Birdw. (Burseraceae) gum resin on rats with persistent inflammation. J Altern Complement Med 2005; 11: 323-331.
102. Acebo E et al. Allergic contact dermatitis from Boswellia serrata extract in a naturopathic cream. Contact Dermatitis 2004; 51: 91-92.
103. Burlando B et al. Comparison of the irritation potentials of Boswellia serrata gum resin and of acetyl-11-keto-beta-boswellic acid by in vitro cytotoxicity tests on human skinderived cell lines. Toxicol Lett 2008; 177: 144-149.
104. Kimmatkar N et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trial. Phytomedicine 2003; 10: 3-7.
105. Janssen G et al. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Klin Padiatr 2000; 212: 189-195.
106. Reising K et al. Determination of boswellic acids in brain and plasma by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 2005; 77: 6640-6645.
107. Krüger P et al. Metabolism of boswellic acids in vitro and in vivo. Drug Metab Dispos 2008; 36: 1135-1142.
108. Singh S et al. Boswellic acids: a leukotriene inhibitor also effective through topical application in inflammatory disorders. Phytomedicine 2008; 15: 400-407.
109. Sterk V et al. Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. Planta Med 2004; 70: 1155-1160.
110. Sharma S et al. Pharmacokinetic study of 11-keto beta-boswellic acid. Phytomedicine 2004; 11: 255-260.
111. Büchele B, Simmet TJ. Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by highperformance liquid chromatography and photodiode array detection. Chromatogr B Analyt Technol Biomed Life Sci 2003; 795: 355-362.
112. Sander O et al. [Is H15 (resin extract of Boswellia serrata, "incense") a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study]. Z Rheumatol 1998; 57: 11-16.
113. Schweizer S et al. Workup-dependent formation of 5-lipoxygenase inhibitory boswellic acid analogues. J Nat Prod 2000; 63: 1058-1061.